000154419 001__ 154419
000154419 005__ 20240229123101.0
000154419 0247_ $$2doi$$a10.2196/16413
000154419 0247_ $$2pmid$$apmid:32242518
000154419 0247_ $$2altmetric$$aaltmetric:78969263
000154419 037__ $$aDKFZ-2020-00750
000154419 041__ $$aeng
000154419 082__ $$a610
000154419 1001_ $$0P:(DE-He78)39ab513728727300b8bd91be7120b69d$$aGruner, Laura$$b0$$eFirst author$$udkfz
000154419 245__ $$aEffect of Various Invitation Schemes on the Use of Fecal Immunochemical Tests for Colorectal Cancer Screening: Protocol for a Randomized Controlled Trial.
000154419 260__ $$aToronto$$c2020
000154419 3367_ $$2DRIVER$$aarticle
000154419 3367_ $$2DataCite$$aOutput Types/Journal article
000154419 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1600867854_25390
000154419 3367_ $$2BibTeX$$aARTICLE
000154419 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000154419 3367_ $$00$$2EndNote$$aJournal Article
000154419 500__ $$a#EA:C070#LA:C070#
000154419 520__ $$aFecal occult blood testing has been offered for many years in the German health care system, but participation rates have been notoriously low.The aim of this study is to evaluate the effect of various personal invitation schemes on the use of fecal immunochemical tests (FITs) in persons aged 50-54 years.This study consists of a three-armed randomized controlled trial: (1) arm A: an invitation letter from a health insurance plan including a FIT test kit, (2) arm B: an invitation letter from a health insurance plan including an offer to receive a free FIT test kit by mail upon easy-to-handle request (ie, by internet, fax, or reply mail), and (3) arm C: an information letter on an existing colonoscopy offer (ie, control). Within arms A and B, a random selection of 50% of the study population will receive reminder letters, the effects of which are to be evaluated in a substudy.A total of 17,532 persons aged 50-54 years in a statutory health insurance plan in the southwest of Germany-AOK Baden-Wuerttemberg-were sent an initial invitation, and 5825 reminder letters were sent out. The primary end point is FIT usage within 1 year from receipt of invitation or information letter. The main secondary end points include gender-specific FIT usage within 1 year, rates of positive test results, rates of colonoscopies following a positive test result, and detection rates of advanced neoplasms. The study was launched in September 2017. Data collection and workup were completed in fall 2019.This randomized controlled trial will provide important empirical evidence for enhancing colorectal cancer screening offers in the German health care system.German Clinical Trials Register (DRKS) DRKS00011858; https://bit.ly/2UBTIdt.DERR1-10.2196/16413.
000154419 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000154419 588__ $$aDataset connected to CrossRef, PubMed,
000154419 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b1$$udkfz
000154419 7001_ $$00000-0003-3322-2948$$aLudwig, Leopold$$b2
000154419 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3$$eLast author$$udkfz
000154419 773__ $$0PERI:(DE-600)2719222-2$$a10.2196/16413$$gVol. 9, no. 4, p. e16413 -$$n4$$pe16413$$tJournal of medical internet research / Research Protocols Research Protocols [...]$$v9$$x1929-0748$$y2020
000154419 909CO $$ooai:inrepo02.dkfz.de:154419$$pVDB
000154419 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)39ab513728727300b8bd91be7120b69d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000154419 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000154419 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000154419 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000154419 9141_ $$y2020
000154419 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000154419 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000154419 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000154419 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000154419 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review
000154419 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000154419 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000154419 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index
000154419 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000154419 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000154419 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000154419 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000154419 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000154419 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000154419 980__ $$ajournal
000154419 980__ $$aVDB
000154419 980__ $$aI:(DE-He78)C070-20160331
000154419 980__ $$aI:(DE-He78)C120-20160331
000154419 980__ $$aI:(DE-He78)HD01-20160331
000154419 980__ $$aUNRESTRICTED